Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  DNA damage >  PARP inhibitors >  4-iodo-3-nitrobenzamide

4-iodo-3-nitrobenzamide

Basic information Safety Supplier Related

4-iodo-3-nitrobenzamide Basic information

Product Name:
4-iodo-3-nitrobenzamide
Synonyms:
  • 4-iodo-3-nitrobenzamide
  • Iniparib
  • 109775
  • INIPARIB; NSC-746045; IND-71677; BSI 201; BSI201
  • CS-420
  • BSI-201
  • IND-71677
  • NSC-746045
CAS:
160003-66-7
MF:
C7H5IN2O3
MW:
292.03
EINECS:
685-396-9
Product Categories:
  • Inhibitors
  • Antineoplastic
  • Inhibitor
Mol File:
160003-66-7.mol
More
Less

4-iodo-3-nitrobenzamide Chemical Properties

Boiling point:
344.8±32.0 °C(Predicted)
Density 
2.055±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,Store in freezer, under -20°C
solubility 
DMSO: soluble5mg/mL, clear
form 
powder
pka
14?+-.0.50(Predicted)
color 
white to beige
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
More
Less

Safety Information

Hazard Codes 
Xn
Risk Statements 
22-36-43
Safety Statements 
26
WGK Germany 
3
More
Less

4-iodo-3-nitrobenzamide Usage And Synthesis

Description

Iniparib (160003-66-7) was originally thought to be a PARP1 inhibitor but this is controversial.1,2?Inhibits ionizing radiation-induced single-stranded DNA break repair in lymphoid cell lines?in vivo.3?Inhibits growth of certain breast cancer cell lines?in vitro. Iniparib non-selectively modifies cysteine-containing proteins in tumor cells.4

Uses

Iniparib is an irreversible PARP1 inhibitor. Studies show that potential therapeutic agent for the treatment of cancer, including triple-negative breast cancer.

Uses

Iniparib (BSI-201) is an antineoplastic originally thought to be a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor. Recent studies indicate Iniparib is not a PARP-1 inhibitor, and its mechanism of action is currently unknown.

Uses

Poly(ADP-ribose) polymerase (PARP) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is activated by DNA damage. Inhibiting its activity has been linked to synthetic lethality and loss of either of the breast cancer susceptibility genes, BRCA1 and BRCA2. BSI-201 is an irreversible, noncompetitive inhibitor of PARP1 that disrupts binding between PARP1 and DNA by interacting with the DNA binding domain. It produces rapid apoptosis in various cancer cell lines with IC50 values ranging from 40-128 μM and is not toxic in Syrian hamsters at doses as high as 200 mg/kg. In phase II clinical studies, BSI-201, in combination with carboplatin and gemcitabine, has produced promising results in "triple-negative" breast cancers, increasing median overall survival from 7.7 months to 12.3 months.

References

1) Sinha?et al. (2014),?Downfall of iniparib: a PARP inhibitor that doesn’t inhibit PARP after all; J. Natl. Cancer Inst.,?106?447 2) Mateo?et al.?(2013),?Appraising iniparib, the PARP inhibitor that never was –what must we learn?;?Nat. Rev. Clin. Oncol.,?10?688 3) Ma?et al. (2012),?Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus; Proc. Natl. Acad. Sci. USA,?109?6590 4) Liu?et al. (2012),?Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor; Clin. Cancer Res.,?18?510

4-iodo-3-nitrobenzamideSupplier

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Capot Chemical Co., Ltd
Tel
+86 (0) 571 85 58 67 18
Email
sales@capotchem.com
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202
Email
jerry.ma@hanhonggroup.com
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com
Shanghai Ennopharm Co., Ltd.
Tel
+86 (21) 6435-5022